3月4日,翰森制药(03692)发布公告,宣布其创新药昕越®(伊奈利珠单抗注射液)的第二项上市许可申请已获国家药品监督管理局(NMPA)受理。该产品用于治疗免疫球蛋白G4相关性疾病(IgG4-RD)。值得注意的是,该适应症已于2025年2月8日被NMPA纳入优先审评审批程序,显示出公司在新药开发方面的积极进展。昕越®的研发背景涉及与Viela Bio的许可协议,该公司在2021年被Horizon ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.